HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in the following upcoming investor conferences in September:
Morgan Stanley (NYSE:) 22nd Annual Global Healthcare Conference
Date: Wednesday, September 4th, 2024 at 4:55 p.m. ET
Location: New York, NY
Format: Fireside Chat
Cantor Fitzgerald Global Healthcare Conference 2024
Date: Thursday, September 19th, 2024 at 10:55 a.m. ET
Location: New York, NY
Format: Fireside Chat
Live webcasts of the fireside chats and panel will be available by visiting the Investors & Media section of the Arcus Biosciences (NYSE:) website at www.arcusbio.com. Replays will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39, and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821933473/en/
Investor Inquiries
Pia Eaves (Banerjee)
Head of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com
Media Inquiries
Holli Kolkey
VP of Corporate Communications
(650) 922-1269
hkolkey@arcusbio.com
Source: Arcus Biosciences
